Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease. According to the insights of surveyed U.S. and European pulmonologists, greater reduction in exacerbation rate and greater improvement in quality of life are key areas of unmet need for moderate to severe asthma. Furthermore, novel agents with strong efficacy in reducing the rate of exacerbations will have considerable influence on physician prescribing decisions as competition among pharmacological agents rapidly increases in the moderate to severe asthma market.
- Asthma - Unmet Need - Detailed, Expanded Analysis (Moderate To Severe Asthma)
Author(s): Eun-Jin Yang, PhD
Eun-Jin Yang, Ph.D. is a senior business insights analyst at Decision Resources Group. She has authored market research reports analyzing physician, payer, and market trends in asthma, COPD, Lupus, and other autoimmune diseases.
Her prior experience includes publishing pharmaceutical and biotechnology company-focused industry research articles as a cofounding analyst in the Harvard Biotechnology Club and helping to commercialize inventions in various therapeutic areas from Massachusetts General Hospital and Brigham and Women’s Hospital. She finished her postdoctoral fellowships at Boston Children’s Hospital, Harvard University, and Columbia University. She received her Ph.D. at the University of Texas at Austin.